Healthy volunteers test new diabetes drug formulation

NCT ID NCT07056517

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage study looked at how healthy adults process a drug called lobeglitazone, given as two different tablet types (a standard tablet and a melt-in-the-mouth tablet). Twenty-one participants took single doses under fasting and fed conditions to measure drug levels and safety. The goal was to gather basic information, not to treat any disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

lobeglitazone

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

More trials for these conditions

Other studies related to the condition(s) this trial covers.

Contacts and locations

Locations

  • Nucleus Network Pty Ltd.

    Melbourne, Victoria, 3004, Australia